Stock ANNX ANNEXON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Annexon, Inc.

Equities

ANNX

US03589W1027

Real-time Estimate Cboe BZX
Other stock markets
 14:04:55 2024-04-29 EDT 		5-day change 1st Jan Change
4.775 USD +1.60% Intraday chart for Annexon, Inc. +5.17% +5.29%
04-01 JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating MT
03-27 Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ANNEXON REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(4)
AQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GL
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
GL
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
GL
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
GL
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
GL
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
AQ
ANNEXON REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(4)
AQ
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
GL
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
AQ
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
GL
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
GL
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Annexon : ANX1502 First in Human SAD / MAD Data Overview
PU
Annexon : ARCHER Trial Visual Acuity Results in Geographic Atrophy
PU
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
GL
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
GL
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANNX Stock
  4. News Annexon, Inc.
  5. Press Releases